Responsable/s del laboratorio



The research interests of the CCG group lie at the interface between Chemistry and Biology, by means of molecular modeling and computational chemistry applied to the understanding of ligand-receptor interactions and molecular recognition processes relevant for drug design. We combine these investigations with structural studies, synthesis of compounds and biological studies in close collaboration with international groups, within a multidisciplinary and integrative approach.

We are focused on the study of the molecular recognition processes involving Pattern Recognition Receptors (PRRs), such as Toll-like receptors (main actors in innate immunity), and Galectins (beta-galactoside-binding lectins that play an important role in infection, inflammatory diseases and tumor progression). Despite the number of available 3D structures, the molecular basis of the interaction and response, at atomic level, are still elusive. The global goal is to understand the molecular details of ligand recognition as a source of new compounds able to modulate the target behaviour with possible therapeutic applications.



Financianción Actual

MINECO. CTQ2017-88353-R. Computational studies of innate immunity molecular mechanisms: Toll-like receptors.

Comunidad de Madrid. S2010/BMD-2316. Biología y fisiopatología del sistema del complemento.

Financianción Previa

MINECO. CTQ2014-57141-R. Molecular Pattern Recognition Receptors: Computational Chemistry Insights for Drug Design and Innate Immunity Modulation.

Marie Skłodowska-Curie Actions. Innovative Training Networks. H2020-MSCA-ITN-2014. “TOLLerant” Toll-Like Receptor 4 activation and function in diseases: an integrated chemical-biology approach.

MINECO. CTQ2011-22724. Molecular recognition processes of therapeutic targets involved in immunity and bacterial infection. Approaches from the Computational Chemistry.

Marie Curie Initial Training Networks FP7-PEOPLE-2012-ITN 317297. “GLYCOPHARM. The Sugar Code: from (bio)chemical concept to clinics”.

COST Action BM1003. “Microbial cell Surface determinants of virulence as targets for new therapeutics in cystic fibrosis”.


Más información

Currently no information is available